提供支持(VCBeat) Feb. 10, 2021 -- Suzhou Hanerxi Medical Device Development Co., Ltd. ("Hanerxi"), a leading provider of syringe pens in China, recently announced the completion of a Series Pre-A round worth RMB 10 million, led by Ganhui Capital. Prior to this, Hanerxi has received investments from CCB Medical Growth Fund and Kunshan High-Tech Venture Capital.
Founded in 2014, Hanerxi is dedicated to the R&D of syringe pens (injection pens). The injection pen is a special high-precision syringe used for pen-type medicine. It is characterized by precise and quantitative injection, self-independent medical treatment and safe and convenient use. The injection pen can be used for autonomic treatments of chronic diseases such as insulin, auxin, precision medicine covering interferon, reagents of cells and genes, and biological agents, as well as medical cosmetology.
In order to break the overseas monopoly, after nearly 10 years of R&D, Hanerxi finally launched the automatic pen syringe with independent intellectual property rights. Its safe performance and stable quality can be compared with the top overseas products.
The injection pen independently developed by Hanerxi is made of high lubrication materials. Its basic structure is designed from original research and has the patent of its extensible basic structure. The dosing adjustment enables users to inject "blindly" in addition to the precise scale display. You can change the borosilicate glass sleeve. The standard type of the pen can be used 5000 times, ensuring more than 2000 times of accurate injection. The disposable type of the pen is designed to inject 500 times, ensuring more than 100 times of accurate injection.
About Ganhui Capital
GanHui Capital is a cutting-edge venture capital firm based in Suzhou, mainly investing in growth-stage projects in the fields of health care, new materials, new energy, etc. Mr. Chang Yubao, the founder, has more than ten years of experience as a senior executive in well-known investment institutions.
渝公网安备 50011202502165号
